Use of data mining at the Food and Drug Administration-Reference-Cited by-同舟云学术

Use of data mining at the Food and Drug Administration

Published:2015-07-23 Issue:2 Volume:23 Page:428-434
ISSN:1527-974X
Container-title:Journal of the American Medical Informatics Association
language:en
Short-container-title:

Author:

Duggirala Hesha J¹,Tonning Joseph M²,Smith Ella³,Bright Roselie A⁴,Baker John D¹,Ball Robert⁵,Bell Carlos²,Bright-Ponte Susan J¹,Botsis Taxiarchis⁵,Bouri Khaled⁴,Boyer Marc³,Burkhart Keith²,Steven Condrey G⁶,Chen James J⁷,Chirtel Stuart³,Filice Ross W⁴,Francis Henry²,Jiang Hongying⁸,Levine Jonathan⁴,Martin David⁵,Oladipo Taiye³,O’Neill Rene⁸,Palmer Lee Anne M.¹,Paredes Antonio⁹,Rochester George⁹,Sholtes Deborah⁹,Szarfman Ana²,Wong Hui-Lee⁸,Xu Zhiheng⁸,Kass-Hout Taha⁴

Affiliation:

1. Center for Veterinary Medicine, FDA

2. Center for Drug Evaluation and Research, FDA

3. Center for Food Safety and Applied Nutrition, FDA

4. Office of the Commissioner, FDA

5. Center for Biologics Evaluation and Research, FDA

6. Office of Regulatory Affairs, FDA

7. National Center for Toxicological Research, FDA

8. Center for Devices and Radiological Health, FDA

9. Center for Tobacco Products, FDA

Abstract

Abstract Objectives This article summarizes past and current data mining activities at the United States Food and Drug Administration (FDA). Target audience We address data miners in all sectors, anyone interested in the safety of products regulated by the FDA (predominantly medical products, food, veterinary products and nutrition, and tobacco products), and those interested in FDA activities. Scope Topics include routine and developmental data mining activities, short descriptions of mined FDA data, advantages and challenges of data mining at the FDA, and future directions of data mining at the FDA.

Publisher

Oxford University Press (OUP)

Subject

Health Informatics

Link

http://academic.oup.com/jamia/article-pdf/23/2/428/34147675/ocv063.pdf

Reference61 articles.

1. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment;Guidance for Industry,, 2005

2. A model for the future conduct of pharmacovigilance;Waller;Pharnaccoepidemiol Drug Saf.,2003

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A national analysis of systemic adverse events of beta-blockers used for glaucoma therapy;Cutaneous and Ocular Toxicology;2024-09-12

2. Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study;BMC Pharmacology and Toxicology;2024-08-09

3. Signal of dementia with proton pump inhibitor after minimizing competition bias: an updated disproportionality analysis;Expert Opinion on Drug Safety;2024-08-05

4. Disproportionality analysis of data from VigiBase and other global product safety databases on toxicity of iron chelating agents;Expert Opinion on Drug Safety;2024-08

5. Hypersensitivity Reactions Induced by Iodinated Contrast Media inRadiological Diagnosis: A Disproportionality Analysis Based on the FAERSDatabase;Current Medical Imaging Reviews;2024-07-24